EntryPoint Capital’s Vaxcyte PCVX Stock Holding History

EntryPoint Capital’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-932	Closed	-$58.5K	–	1670
2023 Q4	$58.5K	Buy	+932	New	+$48.4K	0.06%	639

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EntryPoint Capital's PCVX Position: Q1 2024 in Review

EntryPoint Capital sold out of Vaxcyte (PCVX) in Q1 2024, closing a stake of 932 shares — an estimated $58.5K sold.

EntryPoint Capital first reported a position in PCVX in Q4 2023 and held it in 1 quarter. The position peaked at $58.5K in Q4 2023. 251 funds tracked by Wall St. Rank hold PCVX as of Q1 2024.

EntryPoint Capital reported no remaining Vaxcyte position as of Q1 2024 after selling out during the quarter.
EntryPoint Capital sold 932 Vaxcyte shares in Q1 2024, an estimated $58.5K.
EntryPoint Capital first reported a position in Vaxcyte in Q4 2023 and held it in 1 quarter.
EntryPoint Capital's Vaxcyte position peaked at $58.5K in Q4 2023.
251 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2024.

Based on EntryPoint Capital's 13F filing for Q1 2024, filed 14 May 2024.